Objectives: RET fusion genes are known driver mutations in papillary thyroid carcinomas (PTCs) and have been described mainly in pediatric PTCs, in which they represent the most common genetic alteration. The aims of this study were to identify RET fusion genes in PTCs (from pediatric as well as adult patients), to correlate them with clinical and histopathological features and to determine the prognostic significance of RET fusion genes based on long-term follow-up of patients with PTC harboring this mutation. Methods: The cohort consisted of 920 PTC samples (fresh frozen tissues) from pediatric and adult patients. Based on the detected mutation, samples were triaged. Samples positive for the BRAF, HRAS, KRAS, NRAS or NTRK fusion gene mutations were excluded from the further RET fusion gene analyses. Samples were analyzed for the presence of RET fusion genes using Real-Time PCR (LC480, Roche) or using the FusionPlex Comprehensive Thyroid and Lung panel (ArcherDx) by next generation sequencing (MiSeq, Illumina). Results: RET fusion genes were detected in 108 (11.7%) PTCs, from which 34/121 (28.1%) were from pediatric and adolescent patients (7-20 years old) and 74/799 (9.3%) were from adult patients. The mean age of diagnosis was 33.0 ± 17.1 years. A total of 20 types of RET fusions were found, including the following partner genes: CCDC6, NCOA4, PRKAR1A, SQSTM1, IKBKG, RASAL2, TPR, ACBD5, RUFY2, BBIP1, AFAP1L2, AKAP13, TRIM27, SPECC1L, FBXO41, GOLGA5, SSBP2, ZMYM2, ERC1, KIAA1217. The RET fusion-positive carcinomas were associated with infiltrative tumor growth, numerous intrathyroidal micrometastases, psammoma bodies, lymph node and distant metastases. Lymph node metastases were found in 31/34 (91.2%) pediatric cases and in 52/71 (73.2%) adult patients. Distant metastases were identified in 9/34 (26.5%) pediatric patients and 11/69 (15.9%) adult patients. Patients responded well to radioiodine treatment, radioiodine-refractory PTCs harboring RET fusions were rare. Three patients (2.8%) died of the disease, in two cases was carcinoma positive for NCOA4/RET and in one case for CCDC6/RET with a TERT C250T co-alteration. Conclusion: In summary, RET fusion genes are an important genetic marker in PTCs associated with aggressive tumor behavior and frequent metastases. RET fusions occurred approximately three times more frequently in pediatric and adolescent patients, in which carcinomas were more advanced, than in adult patients. In conclusion, the genetic molecular testing of RET fusions is important for patients diagnosis and prognosis and also for possible targeted therapy. Supported by AZV NU21-01-00448 and MH CR RVO 00023761.